Myriad Genetics (MYGN) Tops Q2 EPS by 5c; Cuts FY15 Outlook
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.40, $0.05 better than the analyst estimate of $0.35. Revenue for the quarter came in at $184.4 million versus the consensus estimate of $183.41 million.
Myriad Genetics sees FY2015 EPS of $1.50 - $1.55, versus the consensus of $1.85. Myriad Genetics sees FY2015 revenue of $730 - $740 million, versus the consensus of $796.1 million.
Myriad Genetics sees Q3 2015 EPS of $0.38 - $0.40, versus the consensus of $0.57. Myriad Genetics sees Q3 2015 revenue of $180 - $185 million, versus the consensus of $212.3 million.
The company also announced that Peter D. Meldrum, president and chief executive officer, has notified the company of his decision to retire at the conclusion of the fiscal year on June 30, 2015. Pursuant to the company's succession plan, the board of directors has unanimously elected Mark C. Capone, currently president of Myriad Genetic Laboratories, Inc., as Mr. Meldrum's successor. Mr. Capone, a 13-year veteran of the company, has worked closely with Mr. Meldrum and the board in charting the strategic direction and managing the overall business of the company, as well as regularly interfacing with our institutional shareholders.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.